Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Adult Patients With Severe Hemophilia A
Phase 1/2 Study to Assess the Safety and Pharmacokinetics of Subcutaneous Injection of OCTA101 in Previously Treated Adult Patients With Severe Hemophilia A
Sponsor: Octapharma
Terminated
Study was terminated due to SADRs
Other terminated trials from Octapharma
Other Severe Hemophilia A trials with similar outcome
A PHASE1/PHASE2 clinical study on Severe Hemophilia A, this trial is terminated or withdrawn. The trial is conducted by Octapharma and has accumulated 10 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
10 versions recorded-
Mar 2025 — Present [monthly]
Terminated PHASE1/PHASE2
-
Sep 2024 — Mar 2025 [monthly]
Terminated PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
May 2022 — Jul 2024 [monthly]
Terminated PHASE1_PHASE2
Status: Active Not Recruiting → Terminated
-
Sep 2021 — May 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 5 earlier versions
-
Feb 2021 — Sep 2021 [monthly]
Recruiting PHASE1_PHASE2
Status: Active Not Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2020 — May 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2019 — Jan 2020 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Octapharma
For direct contact, visit the study record on ClinicalTrials.gov .